

Investment Review

The Hereford/DSM US Large Cap Growth Sub-Fund appreciated 2.84% for the month of May compared to a 1.41% return for the Russell 1000 Growth Index and a 1.29% return for the S&P 500 including dividends. At the end of May, the Fund was invested primarily in the health care, technology and consumer discretionary sectors, with smaller weights in the financials, materials, industrials and consumer staples sectors.

For the month, the Fund exceeded the benchmark by approximately 140 bps. This was primarily the result of the Manager's selections in technology, as well as the Fund's selections and overweight in health care versus the benchmark. In May, the best performing positions in the portfolio were Cognizant Tech Solutions, NXP Semiconductors, Celgene, Regeneron Pharmaceuticals and Actavis. The worst performers for the month were Priceline Group, Monster Beverage, Invesco, Alexion Pharmaceuticals and Tencent Holdings

Manager's Commentary

DSM's long-standing global economic outlook of steady 3% type growth remains unchanged. With the US and Chinese economies moving steadily forward, and Europe and Japan growing at a rate of roughly 1%, it appears to us that a global recession is unlikely. While first quarter GDP in the US was weak, it is possible that second quarter GDP will bounce to the upside, as it did last year. If American businesses continue to hire workers at the recent pace, the economy could reach full employment by year-end. Lower unemployment may cause the Federal Reserve to increase rates by the end of 2015, although the pressure to raise rates is offset by weak income growth statistics. It is likely that revenue growth, as represented by that of the S&P 500, will be flattish in 2015 due to the strong dollar and the decline in revenues at energy-producing companies. These two variables may cause earnings growth to appear weak for the market as a whole, but in our view, the underlying strength of the economy is what investors will focus on.

Of particular interest recently are rising bond yields in the developed world. Rates in the US, Europe and Japan have all moved upward in recent weeks. From an historic perspective, rates are still quite low. However investor losses in the bond markets may exceed \$400 billion dollars and might possibly cause capital to flow out of bonds and into equities. Nevertheless, in today's world, economies are growing slowly, commodity prices are weak, deflation is a possibility and wage growth is minimal. With low interest rates throughout the developed world, investors have few investment alternatives. As a result, we believe stock prices should move higher.

We continue to be concerned that serious global economic problems might well result from various geopolitical factors, particularly in the Ukraine and the Middle East, as well as slow growth in Europe and potential issues relating to the situation in Greece. However, these risk factors are well known to investors and we remain cautiously optimistic that global equity markets will trend upward.

The portfolio continues to be focused on unique global businesses that have been identified, and are continuously subject to analysis, by our ten-member investment team. We believe that the valuation of the portfolio, at 20.1x next-four-quarter earnings through June of 2016, and 18.3x 2016 earnings, based on our calculations, continues to be attractive in the current slow growth economic environment and relative to the market. We also continue to project a mid-to-high "teens" earnings growth rate through 2018. Additionally, the portfolio holdings remain characterized by strong balance sheets and significant free cash flow.


Key Information

NAV A Shares (30/01/15) US\$ 164.59
 Total Fund Size (all share classes) US\$ 134.9m

Strategy Assets US\$ 4,824.7m^(a)
 Fund Launch Date 29-Nov-07

Monthly Performance (%)													
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
HF-DSM US LCG	-1.5	5.9	-0.1	-0.7	2.8								6.5
Russell 1000 Growth^(c)	-1.5	6.7	-1.1	0.5	1.4								5.8
S&P 500^(c)	-3.0	5.7	-1.6	1.0	1.3								3.2

Period Performance (%)	YTD	2014	2013	2012	2011	2009	2009	2008	2007	2006	2005	2004	2003	Cumulative	Annualised
HF-DSM US LCG Returns^(b)	6.5	9.7	34.1	18.2	(2.0)	21.9	22.8	(39.3)	18.7	9.8	11.4	9.4	25.2	149.4	7.7%
Russell 1000 Growth^(c)	5.8	13.1	33.5	15.3	2.6	16.7	37.2	(38.4)	11.8	9.1	5.3	6.3	29.7	121.4	6.7%
S&P 500^(c)	3.2	13.7	32.4	16.0	2.1	15.1	26.5	(37.0)	5.5	15.8	4.9	10.9	28.7	125.8	6.8%



Top Ten Holdings

Actavis	Google (Cl. A & C)
Alexion Pharmaceuticals	Monsanto
Biogen	Priceline Group
Celgene	Starbucks
Cognizant Technology Solutions	Visa

Sectoral Breakdown	% of Assets
Health Care	29.5%
Information Technology	29.3%
Consumer Discretionary	23.7%
Financials	8.2%
Materials	3.5%
Industrials	3.2%
Consumer Staples	1.9%

Investment Objective

The investment objective of the HF DSM US LCG is to provide capital appreciation principally through investments in US based growing corporations with market capitalizations generally above US\$5 billion. These companies are chosen for their growth prospects, attractive returns, solid business fundamentals and intelligent management. The sub fund may, on an ancillary basis, invest in US-based companies with lower market capitalizations as well as in non-US based companies. The Compartment may invest in American Depositary Receipts and American Depositary Shares. The reference benchmark for this strategy is the Russell 1000 Growth Index.

Fund Codes	Since inception	HF-DSM US LCG	HF-DSM US LCG Composite	R1000 Growth
Bloomberg				
ISIN				
Reuters				
Sedol				
WKN				

Fund Details

Dealing Day	Daily
Dividends	None - income accumulated within the fund
Investment Manager	DSM Capital Partners LLC 116 Radio Circle Drive, Suite 200, Mount Kisco, NY 10549, USA
Management Company	BSI Fund Management S.A. 44F, rue de la Vallée, L-2661 Luxembourg
Custodian	BSI Europe S.A. 122, Rue Adolphe Fischer L-1521 Luxembourg
Legal Advisers	Elvinger, Hoss & Prussen 2 Place Winston Churchill, L-1340 Luxembourg
Auditor	Deloitte Audit S.à.r.l. 560 Rue de Neudorf, L-2220 Luxembourg

Order Transmission Information

Original Applications To:

UBS Fund Services
Attn.: Transfer Agent
33a avenue J.F. Kennedy
L-1855 Luxembourg

Subsequent Applications Only Via Facsimile:

UBS Fund Services
Attn.: Transfer Agent
Fax : (+352) 4410106417
Tel: (+352) 4410106404
Email: sh-ubsfsl-transferagent@ubs.com

- This refers to the total assets invested in the reference strategy managed by the Investment Manager.
- Data and graph depict DSM Composite through November 2007 and Hereford Funds DSM US Large Cap Growth Fund Class A thereafter. Historical gross performance of DSM Large Cap Composite returns (the Reference Strategy) is net of modeled fee and expense typical of Hereford Funds DSM US Large Cap Growth Fund Class A (1.25% fee + 0.25% expense). Fund follows same strategy. Performance presentation incomplete without accompanying footnotes as shown at www.dsmcapital.com.
- Total return including dividends.
- The fund is registered with the BaFin for public distribution in Germany from 17/10/12, registered with the AFM for public distribution in the Netherlands and registered with the AMF for public distribution in France.
- Share Class U has been granted Reporting Status by HMRC as of October 1, 2010.
- Share Class D is German tax registered from October 1, 2010.

France - Centralizing Correspondent as defined by French Regulation:
Société Générale - Order Desk, 32, avenue du Champ de Tir, BP 81236, F-44312 Nantes Cedex 3
Phone: +33/2.51.85.66.40, Fax: +33/2.51.85.58.71

Germany - Paying Agent as defined by German Regulation:
Marcard, Stein & Co - Ballindamm 36, 20095 Hamburg
Phone: +49/40.32.099.556, Fax: +49/40.32.099.206

Switzerland - Representative and Paying Agent as defined by Swiss Regulation:
Société Générale, Zurich Branch, Talacker, 50, P.O. Box 1928, CH-8021 Zurich
Phone: +41/58.272.34.18 Fax: +41/58.272.35.49

Annual Management Charge

Share Class A & U ^(e)	1.25%
Share Class D ^(f)	1.75%

Minimum Investment

Share Class A & U ^(e)	\$100,000 initial / \$10,000 subsequent
Share Class D	\$10,000 initial / \$1,000 subsequent

This document is for information purposes only. It is neither an advice nor a recommendation to enter into any investment. Investment suitability must be determined for each investor, and this fund may not be suitable for all investors. This information does not provide any accounting, legal, regulatory or tax advice. Investors should consult professional advisers to evaluate this information. An investment should be made only on the basis of the Prospectus, the annual and any subsequent semi-annual reports of HEREFORD FUNDS (the "Fund"), a société d'investissement à capital variable, established in Luxembourg and registered under Part I of Luxembourg law of 20 December, approved by the Commission de Surveillance du Secteur Financier (CSSF). These can be obtained from the Fund, from BSI Fund Management S.A., 44F, rue de la Vallée, L-2661 Luxembourg, and any distributor or intermediary appointed by the Fund. No warranty is given, in whole or in part, regarding performance of the Fund. There is no guarantee that its investment objectives will be achieved. Earnings projections are not guarantees of future results and there is no representation that the securities discussed were or will be profitable. Investors should be aware that the value of investments can fall as well as rise and that they may not recover the full amount invested. Past performance is no guide to future performance. The information provided in this document may be subject to change without any warning or prior notice and should be read in conjunction with the most recent publication of the Prospectus of the Fund. While great care is taken to ensure that this information is accurate, no responsibility can be accepted for any errors, mistakes or omission or for future returns. This document is intended for the use of the addressee only and may not be reproduced, redistributed, passed on or published, in whole or in part, for any purpose, without the prior written consent of HEREFORD FUNDS. Neither the CSSF nor any other regulator has approved this document. Full details of the investment policy and objectives are stated in the Prospectus.